Atezolizumab adjuvant (resected NSCLC, 1 year)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ATEZOLIZUMAB`

ID	`REG-ATEZO-ADJUVANT-NSCLC`
Type	Regimen
Status	reviewed 2026-05-07 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-IMPOWER-010-FELIP-2021`

Notes

IMpower010 (Felip LANCET 2021, NCT02486718): adjuvant atezolizumab 1200 mg IV q3w × 16 cycles (1 year) after 1-4 cycles adjuvant platinum-based chemotherapy in completely resected stage IB–IIIA NSCLC. FDA approval Oct-2021 (PD-L1 SP142 ≥1%, stage II–IIIA). PD-L1 SP142 ≥1% stage II–IIIA subgroup: DFS HR 0.66 (95% CI 0.50–0.88). OS data not yet mature at primary analysis.

Used By

Indication

IND-NSCLC-ADJUVANT-ATEZO-PDL1POS - IND-NSCLC-ADJUVANT-ATEZO-PDL1POS